A Phase 1 interventional study of DW5124 and DW5124-R in Mixed Dyslipidemia, sponsored by Daewon Pharmaceutical Co., Ltd.. Completed at 1 site in South Korea. Open to participants aged 19 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-06.
Sponsored by Daewon Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 155 studies in Dyslipidemias with a site in Korea, Republic of — 30 open to participants now, 39 under way, 5 of them phase 3. Dyslipidemias · Korea, Republic of.
Among the 155 studies in Dyslipidemias with a site in Korea, Republic of, this one is the 89th largest by enrollment of the 124 interventional ones that give a count, is one of 14 that started in 2025, is one of 58 in phase 1, and was the 142nd registered.
1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.
Browse Dyslipidemias studies →30 of the 155 studies in Dyslipidemias with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Korea United Pharm. Inc. · Sites in Korea, Republic of
Ages 19–54 · Healthy volunteers
Yonsei University · Sites in Korea, Republic of
Ages 19–85
Sin Gon Kim · Sites in Korea, Republic of
Ages 70+
Novartis Pharmaceuticals · Sites in Korea, Republic of
Ages 18–100
Korea United Pharm. Inc. · Sites in Korea, Republic of
Ages 19+ · Healthy volunteers
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 19 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
155 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 14 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 55 is below the median of 100 across 986 interventional studies indexed under Dyslipidemias.
Median enrollment 80 across the 124 interventional studies, 5,000 across the 31 observational. Of the 99 that completed or were terminated, 3 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
122 of 155 have an industry lead sponsor. The 10 most frequent:
Daewon Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 7 are open to participants now.
Daewon Pharmaceutical Co., Ltd. has 6 studies filed under Dyslipidemias — fewer than ten, so there is no comparison to draw.
6 of the studies in Dyslipidemias with a site in Korea, Republic of that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT07523971JW PharmaceuticalEfficacy and Safety of Pitavastatin/Ezetimibe in Dyslipidemia Patients With Metabolic Syndrome: An Observational Study | 2026-12 |
| NCT05365425Seoul National University Bundang HospitalCholine Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia | 2026-12-31 |
| NCT05365438Seoul National University Bundang HospitalAtmeg (Atorvastatin and Omega-3 Combination) and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia | 2026-12-31 |
| NCT06293417Korea University Anam HospitalTo Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM | 2027-02-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 155 studies in Dyslipidemias with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aimed to evaluate the safety and pharmacokinetic characteristics of DW5124 and DW5124-R, and the effect of food on DW5124, in healthy adult volunteers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
cross-over
Drug: DW5124 · Drug: DW5124-R
cross-over
Drug: DW5124 · Drug: DW5124-R
cross-over
Drug: DW5124 · Drug: DW5124-R
cross-over
Drug: DW5124 · Drug: DW5124-R
cross-over
Drug: DW5124 · Drug: DW5124-R
cross-over
Drug: DW5124 · Drug: DW5124-R
DW5124 on fasted or fed condition
DW5124-R on fasted or fed condition
Peak Plasma Concentration (Cmax)
Pharmacokinetics of DW5124-fed and DW5124-fasting, Pharmacokinetics of DW5124-fed and DW5124-R-fed
Time frame: up to 72 hour
Area under the plasma concentration versus time curve (AUC)
Pharmacokinetics of DW5124-fed and DW5124-fasting, Pharmacokinetics of DW5124-fed and DW5124-R-fed
Time frame: up to 72 hour
Time to maximum plasma concentration (Tmax)
Pharmacokinetics of DW5124-fed, DW5124-fasting, DW5124-R-fed
Time frame: up to 72 hour
Terminal half life (t1/2)
Pharmacokinetics of DW5124-fed, DW5124-fasting, DW5124-R-fed
Time frame: up to 72 hour
Apparent clearance (CL/F)
Pharmacokinetics of DW5124-fed, DW5124-fasting, DW5124-R-fed
Time frame: up to 72 hour
Apparent volume of distribution (Vd/F)
Pharmacokinetics of DW5124-fed, DW5124-fasting, DW5124-R-fed
Time frame: up to 72 hour
Ran from May 2025 to primary completion in May 2025, 0 months.
Of 77 industry-sponsored phase 1 interventional studies under Dyslipidemias, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 0 months is below that.
Counting every sponsor, half of 83 studies reached it within 2 months; a quarter within 1 and three quarters within 10.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Daewon Pharmaceutical Co., Ltd. →